Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glioblastoma stem cell growth requires DOT1L-MED23 control of enhancer accessibility.

Cell reports·2026
Same author

IGF2 supports glioblastoma growth and immune evasion through a combination of tumor cell-intrinsic and -extrinsic mechanisms.

Neuro-oncology advances·2026
Same author

Drug overdose and suicidal intentionality among young adults in methadone treatment.

The American journal on addictions·2025
Same author

Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile.

EMBO molecular medicine·2025
Same author

Do commercial dog extracts cross-react with <i>Felis domesticus</i> allergen 1.

Allergy and asthma proceedings·2024
Same author

Analysis and visualization of the effect of multiple sclerosis on biological brain age.

Frontiers in neurology·2024
Same journal

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Invisible symptoms in multiple sclerosis and their impact on social role participation: A multidimensional analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Interaction between smoking and <i>HLA-A*02:01</i> in multiple sclerosis progression.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles

Related Experiment Video

Updated: May 19, 2026

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Prolactin in multiple sclerosis.

Simon Zhornitsky1, V Wee Yong, Samuel Weiss

  • 1Multiple Sclerosis Program, Department of Clinical Neurosciences, University of Calgary, Canada.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|August 31, 2012
PubMed
Summary
This summary is machine-generated.

Prolactin (PRL) may influence multiple sclerosis (MS) relapses and has potential for myelin repair. However, its exact role in MS pathophysiology and treatment remains unclear, despite some studies suggesting links between elevated PRL and MS.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Related Experiment Videos

Last Updated: May 19, 2026

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Area of Science:

  • Neuroimmunology
  • Endocrinology

Background:

  • Multiple sclerosis (MS) disproportionately affects women and often shows remission during pregnancy, a state associated with high prolactin (PRL) levels.
  • Preclinical studies in animal models indicate that PRL can promote myelin repair, suggesting therapeutic potential for demyelinating diseases like MS.

Purpose of the Study:

  • To systematically review the existing literature on the association between prolactin (PRL) and multiple sclerosis (MS).
  • To elucidate the potential role of PRL in the pathophysiology and treatment of MS.

Main Methods:

  • A systematic literature search was conducted in PubMed and EMBASE databases.
  • Keywords used included "prolactin" and "multiple sclerosis."
  • Twenty-three studies met the inclusion criteria for the review.

Main Results:

  • Elevated PRL levels may be more prevalent in MS patients compared to healthy controls.
  • Hyperprolactinemia might correlate with clinical relapse in MS, particularly in patients with hypothalamic lesions or optic neuritis, though causality is undetermined.
  • The majority of individuals with MS exhibit normal PRL levels.

Conclusions:

  • The precise impact of prolactin on multiple sclerosis outcomes is currently unclear.
  • Further research is needed to determine if PRL is a causative factor in MS relapses or a consequence of the disease process.
  • The therapeutic potential of PRL for myelin repair in MS requires further investigation.